Credit Agricole S A Grows Stake in TransMedics Group, Inc. $TMDX

Key Points

• Credit Agricole S A significantly increased its stake in TransMedics Group by 116%, acquiring 12,929 shares and bringing its total ownership to 24,079 shares valued at approximately $1.62 million.
• TransMedics Group recently reported $0.92 EPS for the quarter, which surpassed analysts' expectations, and its revenue grew 37.7% year-over-year.
• Institutional investors hold a significant majority of TransMedics Group's shares, with 99.67% ownership, indicating strong institutional interest in the company.

Credit Agricole S A raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 116.0% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 24,079 shares of the company's stock after purchasing an additional 12,929 shares during the period. Credit Agricole S A owned 0.07% of TransMedics Group worth $1,620,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TMDX. NBC Securities Inc. purchased a new position in shares of TransMedics Group during the 1st quarter valued at about $25,000. Hager Investment Management Services LLC lifted its holdings in TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares in the last quarter. CWM LLC boosted its position in shares of TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after purchasing an additional 155 shares during the period. GAMMA Investing LLC boosted its position in shares of TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. increased its stake in shares of TransMedics Group by 46.7% in the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock worth $148,000 after purchasing an additional 700 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TMDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer upped their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Piper Sandler reiterated an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $123.00.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

Shares of TMDX stock traded down $1.76 on Friday, reaching $114.96. The company's stock had a trading volume of 665,581 shares, compared to its average volume of 998,422. The stock's fifty day simple moving average is $120.24 and its 200-day simple moving average is $103.07. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $172.78. The company has a market capitalization of $3.92 billion, a price-to-earnings ratio of 59.57 and a beta of 2.09. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter last year, the business earned $0.35 earnings per share. TransMedics Group's quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.